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 On behalf of the authors of [1].To the Editor:
We are grateful to Drs. Bruno and Mangia for their interest in our 
work [1], and we agree that data on response rates by the degree 
of ﬁbrosis would be useful and would help guide physician s and 
patients in reaching a decision regarding the value of therapy, fol- 
lowing a ‘lead-in’ phase. However, in a retrospec tive analysis of
study subpopulat ions in a trial that was not designed, or pow- 
ered, to answer the question of interest, there is a difﬁcult line 
to be drawn between an ‘appropri ate analysis’ and ‘data dredg- 
ing’. The REALIZE study [2] was powered to investigat e the value 
of telaprevir in patients who had failed to respond to pegylate d
interferon and ribavirin and was designed to include a study 
arm examinin g the value of a ‘lead in’ with pegylated interferon 
and ribavirin. Only half of the enrolled patients therefore received 
a ‘lead-in’ reducing the number of subjects whose response to
pegylated interferon and ribavirin could be assessed . We believe 
that a retrospec tive analysis of patients divided by prior treat- 
ment response and response during ‘lead-in’ is appropriat e, but 
to sub-divid e the population further is, in our view, an analysis 
too far. The number of null-respond er patients with cirrhosis 
who responded during the lead in phase was 7 – in our view to
quote response rates following telaprevir based on such a small 
number of patients is of limited value and is potential ly harmful 
– clinicians and patients should not be encourag ed to base their 
treatment decisions on subset analyses with very wide conﬁ-
dence interval s, as such decisions are likely to be incorrect. We
recognize that studies with other drugs where all patien ts receive 
a lead-in may recruit sufﬁcient patients for a meaningf ul analysis,1260 Journal of Hepatology 20but for telaprevir where the ‘lead in’ is optional and for the REAL- 
IZE study, where only half of the patients received a ‘lead in’, we
believe that further sub-analy ses are not appropriate. We accept 
that others would take a differen t approach to the data and we
accept that the desire for data sometimes overrides the desire 
for informa tive data. Howeve r, we do not believe that publicati on
of results from very small subsets of patients should be
encouraged.Conﬂict of interes t
Consultancy work and advisary boards for Janssen, Roche, Merck,
Gilead, Novartis, BI and BMS.Response asse ssment methodologies in hepa tocellular 
carcino ma: Compl exities in the era of local and system ic treatme nts To the Editor:
Although the mainstay of hepatocell ular carcinoma (HCC) treat- 
ment has been locoregiona l, new systemic agents have demon- 
strated signiﬁcant improvem ent in time-to-pro gression (TTP)
and survival, leading some to postulate TTP as a surrogate of sur- 
vival. While there is some rationale supportin g this concept in
advanced disease, complexi ties in HCC imaging should temper 
expanding this enthusiasm to early/int ermediate disease until 
more robust evidence is available. Several examples of this lack 
of correlation exist in the radiofrequen cy ablation (RFA), chemo- 
embolizatio n (TACE)/radioembolizat ion, and systemic therapy 
literature. Although we agree with EASL-EORTC guidelines that 
mRECIST helps move the ﬁeld forward, several imaging complex- 
ities remain unaddressed [1,2]. These were highlighted by our 
core imaging research group following a formal review of 463 
HCC patients (1818 scans) treated with chemoe mbolizatio n/
radioemboliz ation [3,4].The ﬁrst imaging complexi ty relates to arterial embolic thera- 
pies. Since these are performed at staged interval s, imaging fol- 
low-up involves the simulta neous radiologic interpr etation of
treated/unt reated disease. This creates difﬁculty in assessing 
response; should response only be measured in the treated 
lesion(s)? How should untreated targets be considered if they 
have sufﬁciently enlarged to meet progressive disease criteria? 
Should imaging only be assessed when all tumors have been trea- 
ted and if so, how should patients never completin g all treat- 
ments (toxicities/decompen sation) be reported? [5,6]. These 
methodologi cal nuances are under-re ported in locoregio nal ther- 
apy studies. Accurately assessing response/p rogression (or lack 
thereof) in the liver is critical since HCC progression is predomi -
nantly local [7]. This is also of importan ce since it suggests that 
the clinical sequela e of progression may be depende nt on the 
treatment received (see Clinical scenarios, Supplem entary infor- 
mation). These concepts further suggest that new (automated)13 vol. 58 j 1258–1266
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tools should focus on response and progres sion in the liver (as
opposed to extrahepatic sites).
The second issue relates to ‘‘conﬁrmatory progression’’. Evalu- 
ating cirrhotic livers for new lesions can be quite challengi ng.
Hypervas cularity/wa shout is not a perfect criterion. It is not 
uncommo n for equivocal lesions to becom e suspicious of HCC,
yet at follow-u p, become less conspicuous . Hence, conﬁrmatory
progression (particularly of new nodules) in HCC should be con- 
sidered. This approach will minimize premat ure discont inuation 
of treatment . We have observed this artifact where a ‘‘new 
nodule’’ in a patient on sorafenib is declared as progressive dis- 
ease (PD) with treatment discontinuat ion. At follow -up, despite 
no treatmen t, the lesion has disappeared , suggesting sorafenib 
was prematurely discontinued (PD overcall ).
The third issue relates to retrospec tive adjudication.
Guidelines suggest that an equivocal lesion, ultimately deter- 
mined to represent an HCC, should be retrospectivel y adjudicat ed
to the time it was ﬁrst observed. It is therefore possible to exhibit 
a TTP of 0 if a baseline equivoc al lesion was only later conﬁrmed
to be HCC. Although unlikely, we have observed this phenome -
non in varying magnitud es. In this scenario, retrospective adjudi- 
cation weakens any TTP/surv ival correlation.
The fourth issue relates to the need to capture HCC-relat ed
portal vein thrombosis in response guidelines. Despite no change 
in index lesion size, HCC treatment may result in the retractio n/
disappearanc e of portal vein thrombos is (PVT). We acknowledge 
that mRECIST appropriat ely labels PVT as non-target with subjec- 
tive response/p rogressio n assessment . Imagin g tools that objec- 
tively/consi stently quantify this relevant ﬁnding are needed.
The ﬁfth point involves the interobserver reproducibility of mea-
suring the longest uni/bidimensional diameter of enhancing tissue.
While RFA may result in clear zones of necrosis and viable tissue, this
is not the case with embolotherapies. We have encountered chal-
lenges when multiple readers attempted to reliably deﬁne the same
(or comparable) areas of enhancing tissue following embolotherapy.
This is a critical issue needing further investigation, with solutions
that may potentially require automated imaging tools.
Finally, and potentially most importantly , the mechanism of
action and the time-dep endence of response are often ignored.
Embolic therapies lead to reduced tumor enhancemen t because 
of vascular occlusion. Since this ﬁnding may be observed on a
contrast scan immediately after emboliza tion, this cannot simply 
be labeled as necrosis. Alternati vely, non-embolic therapi es
(Yttrium-90/radiothe rapy/system ic) require time for response 
to manife st and in fact, may not lead to pronounce d ‘‘necrotic’’
features. The lack of reduction in enhancemen t does not neces- 
sarily suggest treatment failure. Rather, it may represent tissue 
in the process of undergoin g cell death, with lack of enhancem ent 
observed at a later date. Furtherm ore, although systemic agents 
may lead to reduced enhancemen t, this ﬁnding of ‘‘necrosis’’
may not necessar ily represent cell death. In fact, tumoral 
enhancem ent may quickly return once the systemic agent is dis- 
continued , suggest ing hypoenh ancement may not necessar ily 
represent ‘‘necrosis’’ as we understand it patholog ically [8,9].
We believe enhancemen t criteria are skewed towards thera- 
pies that mecha nistically cause avascul arity (RFA, TACE), ignoring 
those not depende nt on arteria l occlusion (Y90/radiotherapy/sys- 
temic). The enthusi asm for new imaging methodol ogies should 
be tempered until more controll ed studies are completed, includ- 
ing radiolog y–pathology correlation; there is only one such study 
to date [10]. The above mentioned methodol ogical complexi ties/ Journal of Hepato logy 20nuances, among others , need to be incorporated in future ver- 
sions of guidelin es as we believe this granula rity of detail is
essential when reportin g response in HCC studies.
When it comes to HCC and response assessment , there is still 
a lot of work to do includi ng standardiza tion, interobserv er
reproducib ility, volume analysis, radiology–pathology correlation 
and imaging surrogat es of survival. While automated software 
appears to be an attractive tool for response assessment , further 
research and validation are needed before being able to imple- 
ment these in routine clinical care.1Financial support 
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Efﬁcacy of interfe ron-ba sed antiviral thera py on the risk 
of hepat ocellula r carcinoma of pat ients with chronic hepat itis 
C: Further evide nce in decomp ensation cirrhosis 
To the Editor:
We read with great interest the paper by Eiichi Ogawa and col- 
leagues [1], accepted for publication in the Journal of Hepatology .
The authors perform ed a large-scal e, multicent er, prospectiv e
study and presented importan t data regarding the observatio n
that sustained virological response (SVR) and transient virolog- 
ical response (TVR: deﬁned as relapse or breakthro ugh) were 
associated with a lower risk of develop ment of hepatocellu lar 
carcinoma (HCC) in patien ts with chronic hepatitis C, with or
without cirrhosis, when compared with non-virologi cal 
response (NVR). However, cirrhotic patien ts with advanced dis- 
ease, namely decompen sated cirrhosis, have been excluded from 
their study. No study to date has provided evidence that virus 
suppression and elimina tion after interferon (IFN)-based antivi- 
ral therapy reduce the risk of HCC in this difﬁcult-to-treat pop- 
ulation. We performed a prospectiv e pilot trial to investigate the 
safety and efﬁcacy of pegylated/s tandard IFN- a combin ed with 
ribavirin for decompens ated cirrhosis patients with HCV 
infection.
From January 2008 to January 2011, 50 consecutive, IFN-naïve
HCV decompe nsated cirrhoti c patients were treated with PegIFN- 
a-2b at 1.0–1.5 lg/kg/wee k or standard IFN- a-2b, 3MU, thrice 
weekly, plus ribavirin at 800–1000 mg/day for 48 weeks, with a
low accelerati ng dosage regimen. The diagnos is of decompe n-
sated liver cirrhosis was made when a patient had experi enced 
one or more of the following clinical symptoms: ascites, variceal 
bleeding, spontaneo us bacterial peritonitis (SBP), and enceph a-
lopathy, which referred to Iacobelli s’ and our previous studies 
[2,3]. Patients with HCC, chronic renal failure, unstabl e cardiova s-
cular disease, severe chronic obstructive lung disease, co-infec- 
tion with immuno deﬁciency or hepatitis B viruses, current 
alcohol abuse, platelets <35,000/ ll, neutrophils <1000/ ll, hae- 
moglobin <100 g/L, or Child-Pugh class C were excluded [2,3].
Patients were routinely monitored for SVR, TVR, and NVR accord- 
ing to the accepted guidelines and Ogawa’s study [1,4]. The pri- 
mary end point of our study was the assessment of HCC 
developmen t after treatmen t; the length of the follow-u p period 
was calculated from the end of the antivir al therapy to the diag- 
nosis of HCC or the last follow-u p visit. The secondary end point 
was to investig ate further events of decompen sation after 
treatment.
The baseline characte ristics and clinical prognosis of the 50
studied patients as classiﬁed by treatment outcome, are shown 
in Table 1. There was no HCC developmen t during antiviral treat- 
ment. Of all patients, 9 (18%) required prematur e treatment with- 
drawal because of adverse effects and/or poor virological 
response. Of the studied patients, 21 achieved SVR (42.0%), 15
were TVR (30.0%), and 14 (28.0%) were NVR. Median follow-up 
off-therapy was 29 (range 8–45) months, seven (14%) patien ts
developed HCC, including 2/21 with SVRs (9.5%), 1/15 with TVRs 
(6.7%) and 4 of 14 with NVRs (28.6%), respect ively. During the fol- 
low-up period, 4/21 patients with SVRs (19.0%), 5/15 (33.3%) with 
TVRs and 13 out of 14 without virological response (92.9%) expe- 
rienced further events of decompens ation (p <0.001).
In patients with HCV compensat ed cirrhosis, a signiﬁcant
reduction in the annual incidence of HCC has been reported after 
SVR [5,6]; and Ogawa and colleague s found that compensation cir- 
rhotic patients with TVR also have a lower incidenc e rate of HCC 
compared with patients with NVR. For decompen sation cirrhotic 
patients in our study, although a low number of patients developed 
HCC and the observation period was short, the Kaplan–Meier 
curves for the end point of HCC showed a noticeab le separati on
of both patien ts with SVR and TVR from those with NVR, at approx- 
imately 16 months of post-treatment follow-up (overall: p = 0.048,
SVR vs. TVR: p = 0.887, SVR vs. NVR: p = 0.045, and TVR vs. NVR:
p = 0.089 by Log-rank test) (Supplement ary Fig. 1). It is inconsisten t
with the results of the study showing that HCC developed at com- 
parable rates in decompe nsation cirrhotic patients with and with- 
out SVR during a 5-year follow-u p, upon completi on of the 
combination therapy [7]. One possible explanation for the discrep- 
ant results may be that the efﬁcacy of TVR on the risk of HCC was 
included in no SVR group, in their study [7]. An intriguing ﬁnding
from our study is that 72% (36/50) of decompe nsation cirrhotic 
patients, compared with 68% (102/150) of compens ation cirrhotic 
patients in Ogawa and colleagues’ study, had an undetectab le HCV 
RNA at the end of treatment. Asians have a signiﬁcantly higher 
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